cytosine has been researched along with Dysmyelopoietic Syndromes in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia." | 9.10 | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. ( Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA, 2002) |
| "To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia." | 9.09 | Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. ( Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA, 2001) |
| " Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections." | 7.83 | Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. ( Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S, 2016) |
| "Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5." | 5.10 | Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. ( Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA, 2003) |
| "To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia." | 5.10 | Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. ( Andreeff, M; Baker, SD; Bivins, C; Cortes, JE; Garcia-Manero, G; Giles, FJ; Jolivet, J; Kantarjian, HM; Miller, CB; O'Brien, SM; Thomas, DA, 2002) |
| "To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-nucleoside analog, troxacitabine (BCH-4556), in patients with advanced leukemia." | 5.09 | Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. ( Baker, SD; Beran, M; Bivins, C; Cortes, JE; Giles, FJ; Jolivet, J; Kantarjian, HM; O'Brien, S; Smith, TL; Thomas, DA, 2001) |
| "Hypomethylating agents such as 5-azacytidine or decitabine have been a major breakthrough in the treatment of patients with myelodysplastic syndromes (MDS)." | 4.87 | Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. ( Jabbour, E; Kadia, TM; Kantarjian, H, 2011) |
| " Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections." | 3.83 | Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation. ( Edelmann, A; Hofmann, J; Kühl, JS; Sauerbrei, A; Voigt, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Seethy, AA | 1 |
| Pethusamy, K | 1 |
| Kushwaha, T | 1 |
| Kumar, G | 1 |
| Talukdar, J | 1 |
| Chaubey, R | 1 |
| Sundaram, UD | 1 |
| Mahapatra, M | 1 |
| Saxena, R | 1 |
| Dhar, R | 1 |
| Inampudi, KK | 1 |
| Karmakar, S | 1 |
| Gackowski, D | 1 |
| Gawronski, M | 1 |
| Kerr, C | 1 |
| Radivoyevitch, T | 1 |
| Zarakowska, E | 1 |
| Starczak, M | 1 |
| Abakir, A | 1 |
| Ruzov, A | 1 |
| Maciejewski, JP | 1 |
| Olinski, R | 1 |
| Liu, X | 1 |
| Zhang, G | 1 |
| Yi, Y | 1 |
| Xiao, L | 1 |
| Pei, M | 1 |
| Liu, S | 1 |
| Luo, Y | 1 |
| Zhong, H | 1 |
| Xu, Y | 1 |
| Zheng, W | 1 |
| Shen, J | 1 |
| Poloni, A | 1 |
| Goteri, G | 1 |
| Zizzi, A | 1 |
| Serrani, F | 1 |
| Trappolini, S | 1 |
| Costantini, B | 1 |
| Mariani, M | 1 |
| Olivieri, A | 1 |
| Catarini, M | 1 |
| Centurioni, R | 1 |
| Alesiani, F | 1 |
| Giantomassi, F | 1 |
| Stramazzotti, D | 1 |
| Biagetti, S | 1 |
| Alfonsi, S | 1 |
| Berardinelli, E | 1 |
| Leoni, P | 1 |
| Calvo, X | 1 |
| Nomdedeu, M | 1 |
| Navarro, A | 1 |
| Tejero, R | 1 |
| Costa, D | 1 |
| Muñoz, C | 1 |
| Pereira, A | 1 |
| Peña, O | 1 |
| Risueño, RM | 1 |
| Monzó, M | 1 |
| Esteve, J | 1 |
| Nomdedeu, B | 1 |
| Coutinho, DF | 1 |
| Monte-Mór, BC | 1 |
| Vianna, DT | 1 |
| Rouxinol, ST | 1 |
| Batalha, AB | 1 |
| Bueno, AP | 1 |
| Boulhosa, AM | 1 |
| Fernandez, TS | 1 |
| Pombo-de-Oliveira, MS | 1 |
| Gutiyama, LM | 1 |
| Abdelhay, E | 1 |
| Zalcberg, IR | 1 |
| Voigt, S | 1 |
| Hofmann, J | 1 |
| Edelmann, A | 1 |
| Sauerbrei, A | 1 |
| Kühl, JS | 1 |
| Stresemann, C | 1 |
| Bokelmann, I | 1 |
| Mahlknecht, U | 1 |
| Lyko, F | 1 |
| Kantarjian, H | 3 |
| Garcia-Manero, G | 4 |
| O'Brien, S | 3 |
| Faderl, S | 2 |
| Ravandi, F | 1 |
| Westwood, R | 1 |
| Green, SR | 1 |
| Chiao, JH | 1 |
| Boone, PA | 1 |
| Cortes, J | 1 |
| Plunkett, W | 1 |
| Craddock, C | 1 |
| Kadia, TM | 1 |
| Jabbour, E | 1 |
| Alvarado, Y | 1 |
| Kantarjian, HM | 4 |
| Cortes, JE | 4 |
| Apostolidou, E | 1 |
| Bivins, C | 3 |
| Giles, FJ | 4 |
| Giles, F | 1 |
| Estey, E | 1 |
| Thomas, DA | 3 |
| Douer, D | 1 |
| Levine, AM | 1 |
| Koller, CA | 1 |
| Jeha, SS | 1 |
| O'Brien, SM | 2 |
| Estey, EH | 1 |
| Abdulkadyrov, KM | 1 |
| Gritsaev, SV | 1 |
| Bessmel'tsev, SS | 1 |
| Martynkevich, IS | 1 |
| Tiranova, SA | 1 |
| Blinov, MN | 1 |
| Osipova, RI | 1 |
| Lehmann, U | 1 |
| Brakensiek, K | 1 |
| Kreipe, H | 1 |
| Gröne, D | 1 |
| Treudler, R | 1 |
| de Villiers, EM | 1 |
| Husak, R | 1 |
| Orfanos, CE | 1 |
| Zouboulis, ChC | 1 |
| Baker, SD | 2 |
| Smith, TL | 1 |
| Beran, M | 1 |
| Jolivet, J | 2 |
| Kiehl, MG | 1 |
| Basara, N | 1 |
| Miller, CB | 1 |
| Andreeff, M | 1 |
| Galvani, DW | 1 |
| Dang, Y | 1 |
| Watson, F | 1 |
| Pumford, D | 1 |
| Galazka, A | 1 |
| Weiner, J | 1 |
| Davies, JM | 1 |
| Cawley, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes[NCT00380653] | Phase 1 | 47 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for cytosine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibod | 2011 |
Role of epigenetic changes in hematological malignancies.
Topics: Animals; Cytosine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Epigenesis, Genetic; | 2004 |
10 trials available for cytosine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Azacytidine causes complex DNA methylation responses in myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytosine; Decitabine; DNA Methylation; Genome, | 2008 |
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinon | 2010 |
Troxacitabine activity in extramedullary myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytosine; Dioxolanes; Fem | 2002 |
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Mon | 2002 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2003 |
[Anticytosine therapy for primary myelodysplastic syndrome].
Topics: Aged; Bone Marrow; Cytosine; Disease Progression; Erythrocyte Transfusion; Female; Hematologic Agent | 2003 |
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Blast Crisis; Cytosine; Dioxolanes; Dose-Response | 2001 |
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Female; Humans; Leukemi | 2002 |
Combination of GM-CSF and cytosine in myelodysplasia results in improved neutrophil function.
Topics: Antigens, CD; Antigens, Differentiation; Blood Cell Count; Bone Marrow; CD11 Antigens; CD18 Antigens | 1992 |
9 other studies available for cytosine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Topics: Bone Marrow; Cytosine; Dioxygenases; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Myelody | 2023 |
5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.
Topics: Biomarkers; Cytosine; Dioxygenases; DNA-Binding Proteins; Humans; Mutation; Myelodysplastic Syndrome | 2020 |
Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Cytosine; Dioxygenases; DNA Methylation; DNA-Bindi | 2013 |
Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes.
Topics: 5-Methylcytosine; Aged; Aged, 80 and over; Bone Marrow; Bone Marrow Cells; Cell Lineage; Cytosine; D | 2013 |
High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome.
Topics: 5-Methylcytosine; Adult; Aged; Aged, 80 and over; Bone Marrow; Cytosine; DNA; DNA Methylation; Femal | 2014 |
TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood.
Topics: 5-Methylcytosine; Adolescent; Case-Control Studies; Child; Child, Preschool; Cytosine; Dioxygenases; | 2015 |
Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.
Topics: Acyclovir; Adenoviridae; Adenovirus Infections, Human; Antibiotic Prophylaxis; Antiviral Agents; Chi | 2016 |
Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
Topics: Antigens, Neoplasm; Chromatin; CpG Islands; Cytosine; DNA Methylation; Epigenesis, Genetic; Hematolo | 2011 |
Intravenous cidofovir treatment for recalcitrant warts in the setting of a patient with myelodysplastic syndrome.
Topics: Adult; Antiviral Agents; Cidofovir; Cytosine; Diagnosis, Differential; Female; Hand; Humans; Infusio | 2006 |